Volume 22, Issue 18 p. 2741-2761
Review

Inhibitors of CA IX Enzyme Based on Polyhedral Boron Compounds

Dr. Michael Kugler

Dr. Michael Kugler

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16610 Prague, Czech Republic

Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 14220 Prague, Czech Republic

Search for more papers by this author
Dr. Jan Nekvinda

Dr. Jan Nekvinda

Institute of Inorganic Chemistry of the Czech Academy of Sciences, Hlavní Husinec, 1001, 25068 Řež, Czech Republic

Search for more papers by this author
Dr. Josef Holub

Dr. Josef Holub

Institute of Inorganic Chemistry of the Czech Academy of Sciences, Hlavní Husinec, 1001, 25068 Řež, Czech Republic

Search for more papers by this author
Dr. Suzan El Anwar

Dr. Suzan El Anwar

Institute of Inorganic Chemistry of the Czech Academy of Sciences, Hlavní Husinec, 1001, 25068 Řež, Czech Republic

Search for more papers by this author
Dr. Viswanath Das

Dr. Viswanath Das

Institute of Molecular and Translational Medicine, Hněvotínská 1333/5, 77900 Olomouc, Czech Republic

Search for more papers by this author
Dr. Václav Šícha

Dr. Václav Šícha

Institute of Inorganic Chemistry of the Czech Academy of Sciences, Hlavní Husinec, 1001, 25068 Řež, Czech Republic

Search for more papers by this author
Dr. Klára Pospíšilová

Dr. Klára Pospíšilová

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16610 Prague, Czech Republic

Search for more papers by this author
Dr. Milan Fábry

Dr. Milan Fábry

Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 14220 Prague, Czech Republic

Search for more papers by this author
Dr. Vlastimil Král

Dr. Vlastimil Král

Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 14220 Prague, Czech Republic

Search for more papers by this author
Dr. Jiří Brynda

Dr. Jiří Brynda

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16610 Prague, Czech Republic

Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 14220 Prague, Czech Republic

Search for more papers by this author
Dr. Václav Kašička

Dr. Václav Kašička

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16610 Prague, Czech Republic

Search for more papers by this author
Dr. Marián Hajdúch

Dr. Marián Hajdúch

Institute of Molecular and Translational Medicine, Hněvotínská 1333/5, 77900 Olomouc, Czech Republic

Search for more papers by this author
Dr. Pavlína Řezáčová

Corresponding Author

Dr. Pavlína Řezáčová

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16610 Prague, Czech Republic

Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 14220 Prague, Czech Republic

Search for more papers by this author
Dr. Bohumír Grüner

Corresponding Author

Dr. Bohumír Grüner

Institute of Inorganic Chemistry of the Czech Academy of Sciences, Hlavní Husinec, 1001, 25068 Řež, Czech Republic

Search for more papers by this author
First published: 03 May 2021
Citations: 14

Graphical Abstract

The review covers several classes of inhibitors specific for carbonic anhydrase IX enzyme that emerged recently from a non-traditional concept. This is characterized by combination of space-filing inorganic (metalla)carborane cluster with sulfamide and sulfonamide binding motif for Zn2+ in the active site. The structural factors essential for attaining high activity and selectivity for the CA IX isoform are discussed. Results from preclinical studies show relevance of these compounds for development of anticancer drugs.

Abstract

This review describes recent progress in the design and development of inhibitors of human carbonic anhydrase IX (CA IX) based on space-filling carborane and cobalt bis(dicarbollide) clusters. CA IX enzyme is known to play a crucial role in cancer cell proliferation and metastases. The new class of potent and selective CA IX inhibitors combines the structural motif of a bulky inorganic cluster with an alkylsulfamido or alkylsulfonamido anchor group for Zn2+ ion in the enzyme active site. Detailed structure-activity relationship (SAR) studies of a large series containing 50 compounds uncovered structural features of the cluster-containing inhibitors that are important for efficient and selective inhibition of CA IX activity. Preclinical evaluation of selected compounds revealed low toxicity, favorable pharmacokinetics and ability to reduce tumor growth. Cluster-containing inhibitors of CA IX can thus be considered as promising candidates for drug development and/or for combination therapy in boron neutron capture therapy (BNCT).

Conflict of interest

The authors declare no conflict of interest.